Effie welcomes Matt Abernethy, a father and biotech executive whose story feels almost too perfectly timed to be real. Matt’s youngest son, Ian (now 13), was diagnosed with classic congenital adrenal hyperplasia (CAH) at age two. While navigating the overwhelm, fear, and daily stress of managing a rare disease, Matt received a cold recruiter call for a CFO role at Neurocrine Biosciences — a company actively developing a treatment for CAH. He and his wife Brittany made the leap of faith, moving their family from Indiana to San Diego. Matt kept his personal connection private for years so he could lead objectively. Eventually, he shared his story in an emotional all-company meeting. Ian later became the first patient to receive the newly approved medication. Matt opens up about being a “dadvocate,” the role of faith through the hardest times, what he would tell his overwhelmed past self, the importance of seeking expert care, and communicating with your spouse. It’s a powerful, hope-filled conversation about divine timing, resilience, and the human side of drug development.


